Insider trade

Alkermes (ALKS): Officer exercised options on 5,000 shares

Craig C. Hopkinson, Officer at Alkermes, reported an option exercise of 5,000 shares.

5,000
Shares · @ $19.34
Traded
Jun 1, 2026
Filed
Jun 1, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 28, 2026, the Board took action to expand Mr. Jackson’s responsibilities and, commensurate with such expansion, to also appoint Mr. Jackson as President of the Company, effective August 1, 2026, and to approve Mr. Jackson’s compensation arrangements for his role as President and CEO, in each case effective August 1, 2026.”
  2. Apr 6, 2026InsiderOfficer sold ~$70K of ALKS shares in the open market
  3. May 1, 2026InsiderOfficer sold ~$301K of ALKS shares in the open market
  4. May 4, 2026InsiderOfficer sold ~$68K of ALKS shares in the open market
  5. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  6. May 20, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 20, 2026, at the 2026 annual general meeting of shareholders (the “Annual Meeting”) of Alkermes plc (the “Company”), the Company’s shareholders approved amendments to the Alkermes plc 2018 Stock Option and Incentive Plan to, among other things, increase the number of the Company’s ordinary shares authorized for issuance thereunder by 5,900,000 (the plan as so amended, the “2018 Plan”).”
  7. May 29, 2026InsiderOfficer sold ~$687K of ALKS shares in the open market
  8. Jun 1, 2026InsiderOfficer sold ~$375K of ALKS shares in the open market

What came next

  1. Jun 4, 2026InsiderOfficer sold ~$88K of ALKS shares in the open market
  2. Jun 12, 2026InsiderDirector sold ~$90K of ALKS shares in the open market
  3. Jul 1, 2026Insider · 1 personInsiders: 2 sales (~$464K)
  4. Jul 6, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  5. Jul 6, 2026InsiderOfficer sold ~$110K of ALKS shares in the open market
  6. Jul 28, 2026Company filing · Form 8-K · ResultsReported its results
  7. Jul 30, 2026CongressDisclosed purchase of ALKS — reported range $15,001 - $50,000
  8. Aug 3, 2026Insider · 3 peopleInsiders: 3 sales (~$2.8M)
  9. Aug 12, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  10. Aug 17, 2026Insider · 1 personInsiders: 2 sales (~$373K)
  11. Sep 1, 2026InsiderOfficer sold ~$423K of ALKS shares in the open market
  12. Sep 3, 2026InsiderOfficer sold ~$98K of ALKS shares in the open market
  13. Sep 14, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 14, 2026, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately, with an initial term expiring at the Company’s 2027 annual general meeting of shareholders.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Alkermes

For Alkermes, OQRO holds 6 insider filings (SEC Form 4 or Form 144) and 2 Congress trade reports dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALKS page.

Other recent filings by Craig C. Hopkinson, EVP R&D, Chief Medical Officer

The full history of Craig C. Hopkinson, EVP R&D, Chief Medical Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Alkermes (ALKS) insider traded, and how much?

Craig C. Hopkinson, Officer at Alkermes, reported an option exercise of 5,000 shares. At $19.34.

When did it happen, and when was it made public?

Traded: Jun 1, 2026. Filed: Jun 1, 2026.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Alkermes recently?

For Alkermes, OQRO holds 6 insider filings (SEC Form 4 or Form 144) and 2 Congress trade reports dated in the last 90 days. They are listed on the ALKS page.

Does this mean ALKS stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Alkermes

Everything OQRO holds on this company is on its ALKS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data